Humanwell Healthcare (600079.SH) Receives German Approval for Midazolam Injection

Stock News12-11

Humanwell Healthcare (600079.SH) announced that its subsidiary, Yichang Humanwell Pharmaceutical Co., Ltd., has received approval from the German Federal Institute for Drugs and Medical Devices (BfArM) for the marketing authorization of Midazolam Injection.

The approved indications for Midazolam Injection include: 1) Conscious sedation before, during, or after diagnostic or therapeutic procedures (with or without local anesthesia); 2) Premedication before anesthesia induction in adults, anesthesia induction, and combined use with other anesthetics for sedation; premedication before anesthesia induction in children; 3) Sedation in intensive care units (ICU).

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment